A subsidiary of pharmaceutical giant Johnson & Johnson (J&J) has pleaded guilty in federal court to misdemeanor charges of marketing a drug for unapproved uses. The guilty plea comes as part of a larger, $81-million settlement signed by J&J to settle government allegations that it illegally marketed its anti-seizure drug Topamax for the treatment of conditions including bipolar disorder and drug and alcohol addiction.